Search
Search Results
##search.searchResults.foundPlural##
-
SICKLE CELL ANAEMIA AND MALARIA
11362PDF: 6954HTML: 23817Figures Malaria and SCK: 202 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
3978PDF: 1037HTML: 3575Untitled: 172Cneo. Fig.1: 108Untitled: 98Untitled: 123Untitled: 127 -
THE EFFECT OF ALPHA THALASSEMIA, HBF and HBC ON HAEMATOLOGICAL PARAMETERS OF SICKLE CELL DISEASE PATIENTS IN IBADAN, NIGERIA. ALPHA THALASSEMIA, HBF and HBC ON HAEMATOLOGICAL PARAMETERS OF SICKLE CELL DISEASE PATIENTS
2256PDF: 964HTML: 65 -
PREVALENCE OF SERIOUS BACTERIAL INFECTIONS IN CHILDREN WITH SICKLE CELL DISEASE AT KING ABDULAZIZ HOSPITAL, AL AHSA Bacterial infections in children with sickle cell diseas
1512PDF: 568HTML: 210 -
CLINICAL ASPECTS OF UNCOMPLICATED AND SEVERE MALARIA
7870PDF: 4076HTML: 7332 -
Spontaneous rupture of malarial spleen: report of two cases
786PDF: 403HTML: 2861jdoe, cover letter.doc: 174 -
-
WHAT UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THALASSEMIA TAUGHT US ABOUT TRANSPLANT IMMUNOGENETICS.
3131PDF: 1128HTML: 1473Untitled: 169Untitled: 160Untitled: 162 -
EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES
2168PDF: 791HTML: 1620Figure 1: 176Table 1: 198 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2049PDF: 1500HTML: 266 -
PEDIATRIC MASTOCYTOSIS: AN UPDATE Chldren' Mastocytosis
1814HTML: 1421PDF: 1071 -
A MULTICENTER EXPERIENCE FROM LEBANON IN CHILDHOOD AND ADOLESCENT ACUTE MYELOID LEUKEMIA:HIGH RATE OF EARLY DEATH IN CHILDHOOD ACUTE PROMYELOCYTIC LEUKEMIA.
2051PDF: 1106HTML: 7685cover letter paper final AML: 211 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2553PDF: 795HTML: 5201 -
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
1441PDF: 758HTML: 196 -
THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2213PDF: 872HTML: 1993Fig 1 Rossi: 172 -
-
IDENTİFİCATİON OF LEİSHMANİA TROPİCA FROM PEDİATRİC VİSCERAL LEİSHMANİASİS İN SOUTHERN MEDITERRANEAN REGION OF TURKEY. Molecular characterization of pediatric visceral leishmaniasis
968PDF: 687HTML: 216 -
PATHOGENESIS OF MALARIA IN TISSUES AND BLOOD
4423PDF: 1909HTML: 17723 -
LIMITED STAGE FOLLICULAR LYMPHOMA: THE ROLE OF RADIATION THERAPY.
3680PDF: 1078HTML: 2277Figure 1: 205 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1578PDF: 797HTML: 155 -
PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC Recommendation for ITP management during COVID
2434PDF: 915HTML: 509 -
CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH
1650PDF: 713HTML: 2331 -
The diagnostic pitfalls of mucormycosis
880PDF: 705HTML: 238 -
NUTRITIONALLY VARIANT STREPTOCOCCI BACTEREMIA IN CANCER PATIENTS: A RETROSPECTIVE STUDY, 1999-2014
2059PDF: 982HTML: 4062Cover Letter: 217Figure 1: 224Figure 2: 225Table 1: 200 -
-
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1528PDF: 1188HTML: 175 -
THE SYSTEMIC MASTOCYTOSIS: RADIOLOGICAL POINT OF VIEW Systemic mastocytosis
1481PDF: 535HTML: 701 -
LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT
1274PDF: 1002HTML: 112 -
NURSING MANAGEMENT OF HAEMORRHAGIC CYSTITIS IN PATIENTS UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANTATION: A MULTICENTRE ITALIAN SURVEY Nursing management of haemorrhagic cystitis
1832PDF: 1041HTML: 226 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
3028PDF: 867HTML: 7158Kost Fig1: 176Kost Fig 2: 174Kost Fig3: 170Kost Fig 4: 184Kost Fig5: 181Kost fig 6: 168 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
3837PDF: 746HTML: 1836







